09:12 AM EDT, 07/30/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Wednesday that a late-stage trial of Kisunla to treat Alzheimer's disease demonstrated a slowdown of decline, which it said continued to improve over three years when compared to an untreated external cohort.

The company also said that earlier initiation of Kisunla in study participants significantly lowered the risk of progression when compared to patients who received Kisunla treatment later.

Eli Lilly ( LLY ) shares were up 1% in recent Wednesday premarket activity.